<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364393">
  <stage>Registered</stage>
  <submitdate>8/06/2013</submitdate>
  <approvaldate>14/06/2013</approvaldate>
  <actrnumber>ACTRN12613000657729</actrnumber>
  <trial_identification>
    <studytitle>A study on the optimum bolus dose of alfentanil for laryngeal mask airway insertion when co-administered with a single standard dose of propofol in children</studytitle>
    <scientifictitle>A study on the optimum bolus dose of alfentanil for laryngeal mask airway insertion when co-administered with a single standard dose of propofol in children</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym>Nil</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Induction of general anaesthesia in children </healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A predetermined bolus dose of alfentanil was injected over 30 seconds, followed by propofol 2.5 mg/kg over 10 seconds. The bolus dose of alfentanil was determined by a modified Dixons up-and-down method, starting from 10 microg/kg (2microg/kg as a step size). Laryngeal mask insertion was attempted 90 seconds after the end of alfentanil injection and the response of patients was classified as either success or failure.</interventions>
    <comparator>N/A-this is an observational study</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the optimum bolus dose of alfentanil for laryngeal mask airway insertion the in children by using Dixon and Massey up and down method </outcome>
      <timepoint>At the time of  LMA insertion </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The incidence and severity of injection pain of propofolThe incidence and severity of injection pain of propofol were assessed using the fourpoint scale : 0 = no pain; 1 = mild
pain (grimace); 2 = moderate pain (grimace + cry); and
3 = severe pain (cry + withdrawal).</outcome>
      <timepoint>during the period of intravenous induction </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of adverse events as recorded in each patient's diary/health record for the trial (e.g.laryngospasm,gapping,cough,hypotention,bradycardia)</outcome>
      <timepoint>during the period of LMA insertion</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>ASA 1 and 2 patients of either gender of the age 3- 7 years undergoing elective surgery under general anaesthesia which can be performed with LMA insertion </inclusivecriteria>
    <inclusiveminage>3</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>7</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>airway malformations, clinical evidence of patients with difficult airway, asthma or any sign of upper respiratory tract infection.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>up and down method</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Psychosocial</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Convenience sample</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>17/06/2013</anticipatedstartdate>
    <actualstartdate>7/08/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate>28/11/2014</actualenddate>
    <samplesize>35</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>China</country>
      <state>Fujian Province</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Yusheng Yao</primarysponsorname>
    <primarysponsoraddress>No.134 Dongjie Street,Fujian Provincial Hospital, Fuzhou, Fujian, China, 350001 </primarysponsoraddress>
    <primarysponsorcountry>China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Yusheng Yao</fundingname>
      <fundingaddress>No.134 Dongjie Street, Fujian Provincial Hospital, Fuzhou, Fujian, China, 350001 </fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Yangqin Chen </sponsorname>
      <sponsoraddress>No.134 Dongjie Street, Fujian Provincial Hospital, Fuzhou, Fujian, China, 350001 </sponsoraddress>
      <sponsorcountry>China</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The use of the laryngeal mask airway in children has increased with increasing day-case surgery in paediatric
patients. Successful insertion of the laryngeal mask
requires adequate mouth opening and sufficient depth
of anaesthesia to minimise the upper airway reflexes and
to prevent the untoward events of coughing, gagging and
laryngospasm. Although propofol is a commonly used induction agent due to its depressant effects on airway reflexes, propofol alone does not prevent undesirable airway responses.Consequently, a potent and short-acting opioid (for example alfentanil ) is often added to facilitate laryngeal mask insertion in adults with minimal haemodynamic changes.However, the optimal bolus dose
of alfentanil for children in this context has not been
established. This study was designed, therefore, to determine the optimal dose of alfentanil required for the
successful insertion of the laryngeal mask airway with a
single bolus dose of propofol at induction (2.5 mg/kg)without a neuromuscular blocking agent in children.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Ethics and Committee of Fujian Provincial Hospital </ethicname>
      <ethicaddress>No.134 Dongjie Street, Fuzhou, Fujian, China, 350001 </ethicaddress>
      <ethicapprovaldate>6/06/2013</ethicapprovaldate>
      <hrec>FJSL-2013-06-06</hrec>
      <ethicsubmitdate>10/05/2013</ethicsubmitdate>
      <ethiccountry>China</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Yusheng Yao</name>
      <address>No.134 Dongjie Street, Fujian Provincial Hospital,Fuzhou, Fujian, China, 350001 </address>
      <phone>+86 13559939629</phone>
      <fax />
      <email>fjslyys@gmail.com</email>
      <country>China</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Yusheng Yao</name>
      <address>No.134 Dongjie Street, Fujian Provincial Hospital,Fuzhou, Fujian, China, 350001 </address>
      <phone>+86 13559939629</phone>
      <fax />
      <email>fjslyys@gmail.com</email>
      <country>China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Yusheng Yao</name>
      <address>No.134 Dongjie Street, Fujian Provincial Hospital,Fuzhou, Fujian, China, 350001 </address>
      <phone>+86 13559939629</phone>
      <fax />
      <email>fjslyys@gmail.com</email>
      <country>China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Yusheng Yao</name>
      <address>No.134 Dongjie Street, Fujian Provincial Hospital,Fuzhou, Fujian, China, 350001 </address>
      <phone>+86 13559939629</phone>
      <fax />
      <email>fjslyys@gmail.com</email>
      <country>China</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>